Hostname: page-component-89b8bd64d-46n74 Total loading time: 0 Render date: 2026-05-07T09:30:25.028Z Has data issue: false hasContentIssue false
  • English
  • Français
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Keywords

MigraineHeadacheMigraine researchGuidelineCorrigendum

Information

Type
Corrigendum
Information
Canadian Journal of Neurological Sciences , Volume 52 , Issue 6 , November 2025 , pp. 1044
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

There is an error in Table 5 of this article, which details the 2012 recommendations for episodic migraine.

In the published table, it notes that nadolol has a recommendation strength of “strong”, which is correct, but the quality of evidence should be listed as “moderate”, not “high”.

It also notes that riboflavin has a recommendation strength of “strong”, but the quality of evidence should be listed as “low”, not “moderate”.

References

Medrea, I, Cooper, P, Lagman-Bartolome, AM, et al. Updated Canadian Headache Society Migraine Prevention Guideline with systematic review and meta-analysis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2025;52:450–72. DOI: 10.1017/cjn.2024.285.CrossRefGoogle Scholar